An estimated 6.7 million Americans aged 65 and older are living with Alzheimer’s disease, the most common form of dementia, accounting for 60-80% of dementia cases. The condition is not normal aging — it is a progressive neurodegenerative disorder caused by abnormal protein accumulation in the brain. While there is still no cure, the past two years have brought the first FDA-approved disease-modifying therapies in two decades, and earlier and more accurate diagnosis is now possible through blood biomarkers and PET imaging.
This guide covers what Alzheimer’s actually is, how it progresses, and what treatments and supports are available. For more on related conditions, see our medical conditions hub and our comprehensive dementia guide.
When to seek emergency care: Sudden cognitive changes, particularly if accompanied by weakness, slurred speech, severe headache, or vision changes, can indicate stroke and warrant immediate emergency evaluation. Severe behavioral disturbance, delirium, or any thoughts of self-harm in caregivers warrant urgent attention; 988 is available 24/7.
What Alzheimer’s Disease Is
Alzheimer’s is a progressive brain disorder characterized by accumulation of amyloid plaques and tau neurofibrillary tangles. These abnormal protein deposits disrupt synaptic function, trigger inflammation, and ultimately cause neuronal death, particularly in the hippocampus and cortical regions controlling memory, language, and judgment.
Per National Institute on Aging data, Alzheimer’s prevalence rises sharply with age — affecting roughly 5% of people 65-74, 13% of those 75-84, and 33% of those 85 and older. The pathological process begins 15-20 years before clinical symptoms appear.
Early Warning Signs
The earliest symptoms typically involve recent memory loss disrupting daily life — repeating questions, missing appointments, struggling to follow recipes, getting lost in familiar places. These are different from normal age-related forgetting (occasionally misplacing keys, taking longer to recall a name).
Other early signs include difficulty with familiar tasks, problems with words in speaking or writing, decreased judgment (financial mistakes, falling for scams), withdrawal from work or social activities, and changes in mood or personality. The Alzheimer’s Association lists 10 warning signs that distinguish concerning changes from typical aging.
The Seven Stages
The Reisberg Global Deterioration Scale describes seven stages, though clinicians more often use mild, moderate, and severe categories. Stages 1-2 represent normal cognition or subjective concerns without objective decline. Stage 3 (mild cognitive impairment) involves measurable deficits noticed by family, with intact daily functioning.
Stage 4 (mild Alzheimer’s) brings clear decline in instrumental activities — managing finances, traveling alone, complex meal preparation. Stage 5 (moderate) requires help with activities like choosing appropriate clothing. Stage 6 (moderately severe) requires assistance with personal care including bathing and toileting. Stage 7 (severe) involves loss of speech, mobility, and ability to feed oneself.
Average duration from diagnosis to death is 4-8 years, but some patients live 20 years with the disease. Progression rate varies substantially among individuals.
Causes and Risk Factors
Most Alzheimer’s cases are sporadic, with age the strongest risk factor. The APOE4 gene variant raises risk: one copy roughly triples lifetime risk; two copies (about 2-3% of the population) raise risk 8-12 fold. Per Mayo Clinic, less than 1% of cases are early-onset (before 65), and a small fraction of these are caused by autosomal dominant mutations in APP, PSEN1, or PSEN2 genes.
Modifiable risk factors include cardiovascular disease, hypertension, diabetes, obesity, smoking, physical inactivity, social isolation, depression, hearing loss, and head injury. The 2024 Lancet Commission report estimated that addressing 14 modifiable factors could prevent or delay nearly half of dementia cases worldwide.
Diagnosis
Diagnosis combines clinical assessment, cognitive testing, structural brain imaging (MRI or CT), and increasingly biomarker testing. Cognitive screens like the MoCA (Montreal Cognitive Assessment) and MMSE quantify deficits. Comprehensive neuropsychological testing characterizes the pattern.
Biomarker advances have transformed diagnosis. Amyloid PET scans, CSF testing for amyloid and tau proteins, and newer blood-based biomarkers can confirm Alzheimer’s pathology, distinguishing it from other causes of dementia like vascular dementia, Lewy body dementia, frontotemporal dementia, and Parkinson’s disease dementia. Workup also rules out reversible causes — B12 deficiency, hypothyroidism, normal pressure hydrocephalus, depression, medication effects.
Treatment Options
Symptomatic medications include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) for mild to moderate disease and memantine for moderate to severe disease. These produce modest, temporary symptomatic improvement in roughly 30-50% of patients. Generic cholinesterase inhibitors cost $10-$30 per month.
The newer category of disease-modifying therapies — anti-amyloid monoclonal antibodies — represents the first treatments that target underlying pathology. Lecanemab (Leqembi) received traditional FDA approval in 2023, and donanemab (Kisunla) in 2024. Both reduce amyloid plaques and slow cognitive decline by roughly 25-35% over 18 months in early-stage Alzheimer’s. Treatment costs $26,000-$32,000 per year, plus PET scans and infusion fees. Medicare covers these treatments for eligible patients with confirmed amyloid pathology.
Side effects of anti-amyloid drugs include amyloid-related imaging abnormalities (ARIA) — brain swelling or microhemorrhages — affecting 10-25% of treated patients. Per Cleveland Clinic, careful patient selection and serial MRI monitoring are required.
Behavioral Symptoms
Roughly 90% of Alzheimer’s patients develop behavioral and psychological symptoms — agitation, depression, anxiety, sleep disturbance, hallucinations, or paranoia — at some point in the disease. Non-pharmacologic approaches (consistent routines, environmental simplification, identifying triggers) are first-line. Brexpiprazole received FDA approval in 2023 for Alzheimer’s-related agitation, the first such approval. SSRIs may help with depression and some agitation.
Caregiving and Support
Alzheimer’s affects entire families. The disease produces caregiving demands that average 6-10 hours per day in the moderate stages, with caregiver depression rates roughly twice the general population. Adult day programs, respite care, home health services, and assisted living memory care all help share the load.
The Alzheimer’s Association (1-800-272-3900) provides 24/7 helpline support, care consultation, and local resources. Long-term care costs in the US run $50,000-$130,000 per year for nursing home care; Medicare does not cover long-term custodial care, leaving families to navigate Medicaid eligibility or long-term care insurance.
Lifestyle and Prevention
Multiple modifiable factors influence Alzheimer’s risk. Regular aerobic exercise, Mediterranean or MIND diet patterns, controlling blood pressure and diabetes, treating hearing loss, maintaining social connection, cognitive engagement, adequate sleep, and avoiding head injury all show association with reduced dementia risk in observational studies.
The FINGER trial and similar multidomain intervention studies suggest combining these strategies can produce meaningful benefit. None constitute prevention with certainty, but the same lifestyle that supports cardiovascular and metabolic health also supports brain health.
When to See a Doctor
Memory or cognitive concerns from the patient or family — particularly when affecting daily activities — warrant evaluation. Primary care can initiate workup; neurology, geriatric medicine, or memory disorder clinics offer comprehensive assessment. Earlier diagnosis matters now more than ever because the new disease-modifying treatments work only in early-stage disease.
Workup costs vary. Cognitive testing is typically covered by Medicare. PET imaging without insurance runs $5,000-$8,000; with Medicare coverage typically $200-$1,000 out-of-pocket. Telehealth-based memory clinics have expanded access to specialty care.
Frequently Asked Questions
Is Alzheimer’s hereditary?
Most cases are not directly inherited. The APOE4 gene variant raises risk substantially but does not guarantee disease. Less than 1% of cases involve dominantly inherited gene mutations, typically presenting with early-onset disease. Family history of Alzheimer’s does increase risk modestly.
What’s the difference between Alzheimer’s and dementia?
Dementia is an umbrella term for cognitive decline severe enough to impair daily function. Alzheimer’s is the specific underlying disease causing 60-80% of dementia cases. Other dementia causes include vascular dementia, Lewy body dementia, frontotemporal dementia, and others — see our dementia guide for the full picture.
Do anti-amyloid drugs cure Alzheimer’s?
No. Lecanemab and donanemab slow disease progression by roughly 25-35% over 18 months in early-stage patients. They do not reverse existing damage or produce normal cognition. They represent the first disease-modifying treatments and may evolve into more effective options.
Can Alzheimer’s be prevented?
No intervention prevents Alzheimer’s with certainty, but multiple modifiable risk factors influence disease risk. Cardiovascular health, exercise, diet, social engagement, sleep, hearing aids when needed, and avoiding head injury all show association with lower dementia risk.
The Bottom Line
Alzheimer’s disease is a progressive but increasingly understandable condition with new treatment options for early-stage disease. Earlier diagnosis matters more than ever — both for access to disease-modifying therapies and for planning. Symptomatic medications, anti-amyloid drugs for eligible patients, behavioral approaches, and caregiver support together can substantially shape the disease trajectory. If memory concerns are arising, a primary care or specialty evaluation is the right first step.